STOCKHOLM, Sept. 13, 2019 /PRNewswire/ -- Attana is invited to present at the National University of Singapore's Life Sciences Institute Core Facilities Day - NUS Medical Sciences Cluster on Thursday September 20th. In particular, Attana is invited to show Attana's leading applications for interaction characterisation of CAR-T cells and tumor tissues.
In collaboration with Attana's partner HVD Life Sciences and NUS Medical Science Cluster, scientists from Attana will present how the company's world leading technology is used for interaction characterisation of drugs interactions with cells, sera and tissues. A particular focus will be on applications for CAR-T cells and tumor tissues. CAR-T cells are a form of immunotherapy, in which T-cells are functionalized with Chimeric Antigen Receptors (CAR) for improved recognition of tumor tissues. The functionalization helps the T-cell recognise cancer tumors and consequently improves their ability to fight the cancer. Attana's technology is used to develop and optimize CAR-T cells and to test and validate their function prior to clinical trials.
See Attana's full publictions list here to learn more about our applications.
For more information, please contact:
Teodor Aastrup
CEO Attana AB
e-mail: teodor.aastrup@attana.com
tel: + 46-8-674-57-00
The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share prices, but is of general interest for the shareholders and hence should be communicated.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
